Abstract 15311: Predict Factors Affected With In-Hospital Clinical Outcomes Between Endovascular Therapy and Fogarty Thrombectomy for Patients With Acute Limb Ischemia: A Large Number Analysis Based on JROAD-DPC Database
Takaaki Ozawa, Kenji Yanishi, Tomotsugu Seki, Jun Yoshimura, Daiki Goto, Hirofumi Kawamata, Hideo Tsubata, Naohiko Nakanishi, Takeshi Nakamura, Kan Zen, Satoaki Matoba- Physiology (medical)
- Cardiology and Cardiovascular Medicine
Background: The etiology of acute limb ischemia (ALI) has been often reported to be embolism caused by atrial fibrillation (Af) and/or atrial flutter (AFL), and thrombosis caused by atherosclerosis. Although endovascular therapy (EVT) or fogarty thrombectomy (Fogarty) is recommended as a primary treatment for patients with ALI, which treatment should be chosen is still controversial.
Aim: To evaluate differences of clinical outcomes between primary treatments for patients with ALI, and identify prognostic predictors.
Methods: This was a retrospective study based on the database in the JROAD-DPC (Japanese Registry of All Cardiac and Vascular Diseases and the Diagnosis Procedure Combination). Figure.1 showed the flow chart of this study. Comparison with EVT-alone and Fogarty-alone group was analyzed using propensity score matching with 16 clinically relevant covariates. Clinical outcomes were death, major adverse cardiovascular events (MACE; myocardial infarction, coronary intervention, heart failure, stroke, cerebral hemorrhage), bleeding complications with bleeding academic research consortium (BARC) type 3-5, and any amputation.
Results: Figure2-4 showed the results of this study. Figure.3 demonstrated that bleeding complications and any amputation in Fogarty-alone group were significantly less than EVT-alone group. Figure.4 revealed that Fogarty tended to decrease an amputation-free survival rate in ALI patients who had no history of peripheral artery disease (PAD) and not administered an antiplatelet before onset.
Conclusions: Fogarty should be selected as the primary treatment as much as possible for ALI patients, especially those without PAD.